{"id":"https://openalex.org/W2809903778","doi":"https://doi.org/10.1111/dom.13457","title":"Empagliflozin compared with glimepiride in metformin\u2010treated patients with type 2 diabetes: 208\u2010week data from a masked randomized controlled trial","display_name":"Empagliflozin compared with glimepiride in metformin\u2010treated patients with type 2 diabetes: 208\u2010week data from a masked randomized controlled trial","alternate_titles":[],"publication_year":2018,"publication_date":"2018-08-07","ids":{"openalex":"https://openalex.org/W2809903778","doi":"https://doi.org/10.1111/dom.13457","mag":"2809903778","pmid":"https://pubmed.ncbi.nlm.nih.gov/29961998"},"language":"en","primary_location":{"id":"doi:10.1111/dom.13457","doi":"https://doi.org/10.1111/dom.13457","is_oa":false,"landing_page_url":"https://doi.org/10.1111/dom.13457","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2809903778"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042381457","display_name":"Martin Ridderstr\u00e5le","orcid":"https://orcid.org/0000-0002-3270-9167","observed_orcids":["https://orcid.org/0000-0002-3270-9167"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Martin Ridderstr\u00e5le","raw_affiliation_strings":["Steno Diabetes Centre, Gentofte, Denmark"],"raw_orcid":"https://orcid.org/0000-0002-3270-9167","affiliations":[{"raw_affiliation_string":"Steno Diabetes Centre, Gentofte, Denmark","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045489578","display_name":"Julio Rosenstock","orcid":"https://orcid.org/0000-0001-8324-3275","observed_orcids":["https://orcid.org/0000-0001-8324-3275"]},"institutions":[{"id":"https://openalex.org/I4210112007","display_name":"Dallas Diabetes Research Center","ror":"https://ror.org/022jeg055","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210112007"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Julio Rosenstock","raw_affiliation_strings":["Dallas Diabetes Research Center at Medical City, Dallas, Texas"],"raw_orcid":"https://orcid.org/0000-0001-8324-3275","affiliations":[{"raw_affiliation_string":"Dallas Diabetes Research Center at Medical City, Dallas, Texas","institution_ids":["https://openalex.org/I4210112007"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101082719","display_name":"Knut Robert Andersen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086058","display_name":"Boehringer Ingelheim (Norway)","ror":"https://ror.org/00emmzb12","country_code":"NO","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210086058"]}],"countries":["NO"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Knut R. Andersen","raw_affiliation_strings":["Boehringer Ingelheim Norway KS, Asker, Norway"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Norway KS, Asker, Norway","institution_ids":["https://openalex.org/I4210086058"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056064349","display_name":"Hans Juergen Woerle","orcid":"https://orcid.org/0000-0003-2595-1411","observed_orcids":["https://orcid.org/0000-0003-2595-1411"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hans J. Woerle","raw_affiliation_strings":["Boehringer Ingelheim International GmbH, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim International GmbH, Ingelheim, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073988431","display_name":"Afshin Salsali","orcid":"https://orcid.org/0000-0003-2763-0486","observed_orcids":["https://orcid.org/0000-0003-2763-0486"]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Afshin Salsali","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"last","author":{"id":null,"display_name":"on behalf of the EMPA\u2010REG H2H\u2010SU trial investigators","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"on behalf of the EMPA\u2010REG H2H\u2010SU trial investigators","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5073988431"],"corresponding_institution_ids":["https://openalex.org/I4210160255"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":3.8174,"has_fulltext":false,"cited_by_count":56,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.94337728,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":98},"biblio":{"volume":"20","issue":"12","first_page":"2768","last_page":"2777"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glimepiride","display_name":"glimepiride","score":0.9990000128746033},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.984000027179718},{"id":"https://openalex.org/keywords/metformin-add-on-therapy","display_name":"metformin add-on therapy","score":0.8679999709129333},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.8939999938011169},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.7680000066757202},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.8410000205039978},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.6930000185966492},{"id":"https://openalex.org/keywords/blood-pressure-reduction","display_name":"blood pressure reduction","score":0.8629999756813049},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.8899999856948853},{"id":"https://openalex.org/keywords/long-term-extension-study","display_name":"long-term extension study","score":0.4650000035762787},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.8870000243186951},{"id":"https://openalex.org/keywords/sulfonylureas","display_name":"sulfonylureas","score":0.9160000085830688}],"concepts":[{"id":"https://openalex.org/C2775887513","wikidata":"https://www.wikidata.org/wiki/Q5373824","display_name":"Empagliflozin","level":4,"score":0.976547122001648},{"id":"https://openalex.org/C2776307423","wikidata":"https://www.wikidata.org/wiki/Q425027","display_name":"Glimepiride","level":4,"score":0.9667033553123474},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8626701831817627},{"id":"https://openalex.org/C2780323712","wikidata":"https://www.wikidata.org/wiki/Q19484","display_name":"Metformin","level":3,"score":0.7595676183700562},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.7452220320701599},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.5876861810684204},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5321604013442993},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.485390305519104},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.45901811122894287},{"id":"https://openalex.org/C204243189","wikidata":"https://www.wikidata.org/wiki/Q1363085","display_name":"Randomization","level":3,"score":0.41673824191093445},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.2588346600532532}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013453","descriptor_name":"Sulfonylurea Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/dom.13457","doi":"https://doi.org/10.1111/dom.13457","is_oa":false,"landing_page_url":"https://doi.org/10.1111/dom.13457","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:29961998","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29961998","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G6433152044","display_name":null,"funder_award_id":"SDCC 3.A Complications","funder_id":"https://openalex.org/F4320318293","funder_display_name":"Steno Diabetes Center Copenhagen"}],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320318293","display_name":"Steno Diabetes Center Copenhagen","ror":"https://ror.org/03gqzdg87"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W1847388060","https://openalex.org/W1981928922","https://openalex.org/W2047094893","https://openalex.org/W2051243940","https://openalex.org/W2052503411","https://openalex.org/W2077109510","https://openalex.org/W2097519488","https://openalex.org/W2101344933","https://openalex.org/W2101374656","https://openalex.org/W2109416725","https://openalex.org/W2117512154","https://openalex.org/W2137069992","https://openalex.org/W2146264128","https://openalex.org/W2146901298","https://openalex.org/W2152413054","https://openalex.org/W2162655989","https://openalex.org/W2171471305","https://openalex.org/W2340312426","https://openalex.org/W2424539745","https://openalex.org/W2474731057","https://openalex.org/W4239088940"],"related_works":["https://openalex.org/W2138863697","https://openalex.org/W2052503411","https://openalex.org/W1682854201","https://openalex.org/W2326091077","https://openalex.org/W1714643869","https://openalex.org/W1899868128","https://openalex.org/W2252418906","https://openalex.org/W2101374656","https://openalex.org/W2558145946","https://openalex.org/W4417507267"],"abstract_inverted_index":{"AIM:":[0],"To":[1],"report":[2],"results":[3],"at":[4,123],"week":[5,149],"208,":[6,150],"including":[7],"a":[8,39,47,112,256,263],"104-week":[9,113],"masked":[10],"extension,":[11],"of":[12,65,145,186,218,260,267],"the":[13,105,119,142,146,151],"EMPA-REG":[14],"H2H-SU":[15],"trial":[16],"in":[17,29,42,57,111,115,155,159,216],"patients":[18,130,187,219,238,268],"with":[19,23,46,72,132,161,239,255,273],"type":[20,73,240],"2":[21,74,241],"diabetes":[22,75],"inadequate":[24],"glycaemic":[25],"control":[26],"on":[27,188,192,220,224],"metformin,":[28],"which":[30,116],"empagliflozin":[31,86,133,162,189,221,243],"25":[32,87,244],"mg":[33,88,94,245],"given":[34,183],"for":[35,95,250],"104":[36,96],"weeks":[37,97,252],"provided":[38],"sustained":[40,55],"reduction":[41],"glycated":[43],"haemoglobin":[44],"(HbA1c)":[45],"small":[48],"but":[49],"statistically":[50],"significant":[51],"benefit":[52],"vs":[53,163],"glimepiride,":[54,135],"reductions":[56],"weight":[58],"and":[59,62,76,128,134,137,190,222,262],"blood":[60],"pressure,":[61],"low":[63],"risk":[64,259],"hypoglycaemia.":[66],"RESEARCH":[67],"DESIGN":[68],"AND":[69],"METHODS:":[70],"Patients":[71,102],"HbA1c":[77,160,254],"53-86":[78],"mmol/mol":[79],"(7%":[80],"to":[81,85,92,100,184,248],"10%)":[82],"were":[83],"randomized":[84,106],"or":[89],"glimepiride":[90,164,193,225],"1":[91],"4":[93],"as":[98,246],"add-on":[99,247],"metformin.":[101],"who":[103],"completed":[104],"treatment":[107,121],"period":[108,144],"could":[109],"participate":[110],"extension":[114,143],"they":[117],"continued":[118],"double-blind":[120],"allocated":[122],"randomization.":[124],"RESULTS:":[125],"Of":[126],"765":[127],"780":[129],"treated":[131],"576":[136],"549":[138],"patients,":[139],"respectively,":[140],"entered":[141],"study.":[147],"At":[148],"adjusted":[152],"mean":[153],"difference":[154],"change":[156],"from":[157],"baseline":[158],"was":[165,182],"-1.96":[166],"mmol/mol,":[167],"95%":[168,173],"CI":[169,174,198,230],"-3.57,":[170],"-0.35":[171],"(-0.18%,":[172],"-0.33,":[175],"-0.03);":[176],"P":[177,201,233],"=":[178],"0.0172.":[179],"Rescue":[180],"therapy":[181,271],"23%":[185],"34%":[191],"(odds":[194,226],"ratio":[195,227],"0.56":[196],"[95%":[197,229],"0.45,":[199],"0.71];":[200],"<":[202,234],"0.0001).":[203,235],"Confirmed":[204],"hypoglycaemic":[205],"adverse":[206],"events":[207],"(plasma":[208],"glucose":[209],"\u22643.9":[210],"mmol/L":[211],"and/or":[212],"requiring":[213],"assistance)":[214],"occurred":[215],"3%":[217],"28%":[223],"0.08":[228],"0.05,":[231],"0.13];":[232],"CONCLUSIONS:":[236],"In":[237],"diabetes,":[242],"metformin":[249],"208":[251],"reduced":[253],"significantly":[257,264],"lower":[258],"hypoglycaemia":[261],"smaller":[265],"proportion":[266],"receiving":[269],"rescue":[270],"compared":[272],"glimepiride.":[274]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2809903778","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":2}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2018-07-10T00:00:00"}
